SMARCB1 and bladder transitional cell carcinoma: We subsequently investigated the efficacy of the pSTAT3 selective inhibitor, TTI-101, in SMARCB1 KO orthotopic BLCA cell line-derived xenografts as well as SMARCB1- deficient PDX model.